Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 7/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21583905 | 0.86 | CTSV (0.50) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL14863738 | 0.85 | CCNC (0.46) | HDAC8LOXL2PIM1PIM2KCNH2 | |
| SCHEMBL16675749 | 0.82 | PRKCI (0.51) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL3321969 | 0.81 | LOXL2 (0.36) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL18492830 | 0.79 | LOXL2 (0.51) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL14860284 | 0.78 | CTSV (0.56) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL17547081 | 0.77 | PFKFB3 (0.48) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL31182034 | 0.77 | PFKFB3 (0.48) | CTSVCTSLCTSSCTSBIRAK1 | |
| SCHEMBL14860466 | 0.76 | CTSL (0.44) | CTSLCTSSHDAC8 | |
| SCHEMBL16597444 | 0.76 | TEK (0.47) | CTSVCTSLCTSSCTSBIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | CTSV 4243/4885CTSL 4195/4885CTSS 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.